Synergy Pharmaceuticals Inc fka SGYPQ

[Snackman]

5 Small Biotechs Receive Shots in the Arm
By
Bret Jensen
Follow
| Nov 12, 2017 | 12:00 PM EST

Stock quotes in this article:
sgyp
,
After the bell on Thursday we got a handful of earnings reports and a couple U.S Food and Drug Administration (FDA) approvals among the small-cap biotech names I often cover in these posts, so let's look at some of the highlights.

Synergy Pharmaceuticals Inc. (SGYP) posted very solid third-quarter results that beat both top- and bottom-line consensus. Its key drug Trulance continues to ramp up impressively since it first hit the market this March. Scripts more than doubled from the second quarter.

The drug should be approved for irritable bowel syndrome with constipation (IBS-C) in January, expanding its potential market by a third. Greater access to insurer programs and Medicare formularies to begin 2018 should boost Trulance's sale trajectory further.

A buyout in 2018 is certainly on potential end game for this name.

https://realmoney.thestreet.com/articles/11/12/2017/5-small-biotechs-receive-shots-arm?puc=yahoo&cm_ven=YAHOO&yptr=yahoo